SCHEMBL6172188

SCHEMBL6172188

O=C(Nc1nccs1)C(CC1CCCCC1)c1ccc(-n2nnnc2C(F)(F)F)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ FFAR2 O15552 2/20 0.54
▸ KCNH2 Q12809 2/20 0.53
▸ GCK P35557 16/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2663494 0.88 FFAR2 (0.56) FFAR2KCNH2GCK
SCHEMBL7613373 0.88 KCNH2 (0.52) FFAR2KCNH2GCK
SCHEMBL2663836 0.88 FFAR2 (0.57) FFAR2KCNH2GCK
SCHEMBL2651023 0.83 APP (0.43) KCNH2GCK
SCHEMBL6172662 0.82 KCNH2 (0.56) FFAR2KCNH2GCK
SCHEMBL6173291 0.81 SLC6A3 (0.39) KCNH2GCK
SCHEMBL2645076 0.80 FFAR2 (0.72) FFAR2KCNH2GCK
SCHEMBL2645075 0.80 FFAR2 (0.72) FFAR2KCNH2GCK
SCHEMBL2657079 0.80 FFAR2 (0.72) FFAR2KCNH2GCK
SCHEMBL2657730 0.80 KCNH2 (0.65) FFAR2KCNH2GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1209362-C Tetrazolyl-phenyl acetamide glucokinase activators HOFFMANN LA ROCHE (CH) 2005-07-06 — — CN claimed
EP-1311504-B1 TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-06-15 — — EP claimed
CN-1466584-A Tetrazolyl-phenyl acetamide glucokinase activators - 2004-01-07 — — CN claimed
US-6388088-B1 ANTIDIABETIC AGENTS HOFFMAN-LA ROCHE INC. 2002-05-14 — — US claimed
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 — — US claimed
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 — — US claimed
CN-1209362-C Tetrazolyl-phenyl acetamide glucokinase activators HOFFMANN LA ROCHE (CH) 2005-07-06 — — CN disclosed
EP-1311504-B1 TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-06-15 — — EP disclosed
CN-1466584-A Tetrazolyl-phenyl acetamide glucokinase activators - 2004-01-07 — — CN disclosed
US-6441180-B1 TO INCREASE INSULIN SECRETION, WHICH MAKES THEM USEFUL FOR TREATING TYPE II DIABETES HOFFMANN-LA ROCHE INC. 2002-08-27 — — US disclosed
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-05-30 — — US disclosed
US-6388088-B1 ANTIDIABETIC AGENTS HOFFMAN-LA ROCHE INC. 2002-05-14 — — US disclosed
US-6369232-B1 ANTIDIABETIC AGENTS HOFFMANN-LA ROCHE INC. 2002-04-09 — — US disclosed
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 — — US disclosed
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 FFAR2 598/4885KCNH2 1679/4885GCK 2/4885
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 FFAR2 598/4885KCNH2 1679/4885GCK 2/4885
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators GCKR, GCK, PFKL FFAR2 606/4885KCNH2 1466/4885GCK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback